Neurodevelopmental Outcomes in Children with Exposure to Prescription Stimulants During Pregnancy
Prenatal exposure to prescription stimulants was not associated with an increased risk of neurodevelopmental disorders in exposed children.
Prenatal exposure to prescription stimulants was not associated with an increased risk of neurodevelopmental disorders in exposed children.
Prenatal exposure to ADHD medications, mostly methylphenidate, was not associated with an increased risk of neurodevelopmental disorders or growth restriction in exposed children.
Maternal SSRI use during pregnancy may be associated with altered brain development in children; however, this study cannot fully rule out contributions of confounding genetic and enviromental factors.
Functional MRI revealed no differences in brain structure of white matter integrity in lithium-exposed versus non-lithium-exposed children born to mothers with bipolar spectrum disorder.
Data from a Nordic register-based study observed a significant increase in risk for autism spectrum disorder and intellectual disability in children with prenatal exposure to topiramate.
Analyzing data from nearly 150,000 children with prenatal antidepressant exposure in two healthcare databases, a recent study finds no association between prenatal exposure to antidepressants and risk for neurodevelopmental disorders.
Maternal ACEs were associated with both newborn amygdala volume and subsequent infant negative emotionality.
Prenatal cannabis exposure was associated with persisting vulnerability to psychopathology throughout early adolescence.
Prenatal exposure to antipsychotic medications was not associated with increased risk of neurodevelopmental disorders in offspring.
Prenatal exposure to valproic acid was associated with an increased risk of autism spectrum disorder in exposed children.